Filarial infection and disease from Brugia malayi Infections and Infestations Filariasis
Conditions
Interventions
100 mg/kg doxycycline or matching placebo for six weeks, 6 mg/kg oral DEC plus 400 mg Albendazole or matching placebo for four months post-commencement of doxycycline treatment.
Sponsors
European Commission (Belgium)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. All male and female subjects, who have given informed consent were evaluated 2. Mean microfilariae more than 5 Mf/ml
Exclusion criteria
Exclusion criteria: 1. Aged less than 12 years 2. Patients receiving medication for chronic illness 3. Anti-filarial treatment in the last year 4. Alcohol or drug abuse 5. Pregnancy 6. Lactation 7. Abnormal renal or hepatic blood chemistry
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Reduction in adverse reaction to DEC and Albendazole treatment. | — |
Primary
| Measure | Time frame |
|---|---|
| Sustained amicrofilaraemia in doxycycline or doxycycline and DEC and Albendazole treated patients compared with DEC and Albendazole treated patients as assessed by levels of microfilariae in night blood at two, four and 12 months. | — |
Countries
Indonesia
Outcome results
None listed